Clinical trials
Breast cancer clinical trials
Cancer that forms in the cells of the breast, the most common cancer in women. We’re tracking 2,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07597993Recruiting
Real-world study of Trastuzumab Deruxtecan for advanced breast cancer
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
MuscatAges 18 years+ - NCT07583485Recruiting
Tucatinib combination therapy for advanced HER2-positive breast cancer
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
Avellino, AVAges 18 years+ - NCT06418594RecruitingPhase 2
Drug combo for HER2-negative breast cancer brain metastasis
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06737926Recruiting
Balance exercises for chemotherapy nerve damage in breast cancer
This study tests whether special balance and coordination exercises can help reduce nerve damage side effects (like numbness or tingling) caused by chemotherapy in breast cancer patients. You may benefit if you have these symptoms and want to improve your balance and movement.
Lahore, Punjab ProvinceAges 30–65 - NCT07498478RecruitingPhase 2
Tinengotinib and fulvestrant for advanced HR+ HER2- breast cancer
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT06770296RecruitingPhase 1
Finding the best dose of pyrotinib for first-line advanced HER2 breast cancer
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Nanjing, JiangsuAges 18–75 - NCT07378319Recruiting
Sugar water injection for post-breast cancer tightness
This study tests whether a simple injection of sugar water (dextrose) around tight chest wall and armpit tissues can relieve pain and improve movement in people who have had breast cancer surgery. It is for people whose symptoms did not get better with standard physical therapy.
Taichung, TaiwanAges 18 years+ - NCT06856200Recruiting
Sirolimus plus palbociclib and fulvestrant for advanced breast cancer
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
ShanghaiAges 18 years+ - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT07306130Enrolling by invitation
Skin care advice for breast cancer patients
This study asks a group of expert healthcare professionals to agree on the best ways to care for the skin of breast cancer patients. It uses a step-by-step online survey process to reach consensus.
CairoAges 25 years+ - NCT07285382RecruitingPhase 2
Dalpiciclib plus letrozole for advanced HR+ HER2- breast cancer
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
Dalian, LiaoningAges 18–75 - NCT06894173Recruiting
Early breast cancer treatment evolution study
This study looks back at treatments given to people with triple-negative or HER2-positive early breast cancer between 2016 and 2021. It aims to understand how treatment approaches have changed over time.
Aviano, PNAges 18 years+ - NCT07242118Recruiting
Radiation therapy for older women with breast cancer
This trial tests a precise, high-dose radiation treatment (called SABR) for older women with early-stage breast cancer who choose not to have surgery. It aims to control the tumor with fewer side effects and may be an option if you have a small, ER+, HER2- tumor that hasn't spread to lymph nodes.
Kansas City, KansasAges 65 years+ - NCT06918184Recruiting
Exercise timing after breast cancer surgery
This study tests whether starting specific physical therapy exercises early or later after breast cancer surgery is better for recovery. It may help women who are at risk for arm and shoulder problems after surgery.
CairoAges 18–65 - NCT06721936Recruiting
Study for menopause symptoms after breast cancer
This trial tests a treatment for menopause-like vaginal symptoms that can happen after breast cancer treatment. It aims to help survivors feel more comfortable.
MadridAges 38 years+ - NCT07140172Recruiting
Radiation or surgery for node-positive breast cancer
This trial compares two treatments for people with breast cancer that has spread to the lymph nodes: radiation therapy to the armpit or surgery to remove the lymph nodes. The goal is to see which approach works best after a tailored surgery to remove the most suspicious lymph nodes.
Bethesda, MarylandAges 18 years+ - NCT07117630RecruitingPhase 2
A new drug combo for advanced breast cancer after standard treatment
This trial tests a new drug combination for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after standard treatments like CDK4/6 inhibitors and hormone therapy. It aims to see if the combination can help when other options have stopped working.
ShanghaiAges 18 years+ - NCT04504747Recruiting
Real-time breast cancer testing during chemotherapy
This trial studies real-time molecular testing in people with breast cancer who are receiving chemotherapy before surgery. The goal is to learn how the cancer changes during treatment and whether this helps guide care around surgery and radiation.
Marseille, MarseilleAges 18 years+ - NCT06905301Recruiting
Study on breast cancer medication with a mobile app
This study compares how well breast cancer patients take their medication (ribociclib) with or without using a mobile app. It aims to see if the app helps patients stick to their treatment plan.
Pskov, RussiaAges 18–90 - NCT06874933RecruitingPhase 2
Chemo plus anlotinib and benmelstobart for HR+/HER2- breast cancer
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
Hangzhou, ZhejiangAges 18–75 - NCT06830382Recruiting
HER2-PET scan for metastatic breast cancer treatment
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
SolnaAges 18 years+ - NCT06679036RecruitingPhase 1/Phase 2
Combination therapy for advanced breast cancer
This trial tests new drug combinations for advanced or metastatic breast cancer. It aims to see if adding HRS-2189, HRS-6209, or HRS-1358 to standard treatments works better. Participants must have tried certain hormone therapies or chemotherapies before.
Harbin, HeilongjiangAges 18–75 - NCT06555068RecruitingPhase 1/Phase 2
Study of HRS-6209 combinations for advanced breast cancer
This trial tests a new drug, HRS-6209, combined with different hormone treatments (fulvestrant, letrozole, HRS-8080, or HRS-1358) for people with advanced breast cancer that has spread or cannot be surgically removed and has worsened after previous treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06492616RecruitingPhase 3
Elacestrant versus standard hormone therapy for early breast cancer
This trial compares a new medicine, elacestrant, to the usual hormone therapy for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a high chance of it coming back. The goal is to see if elacestrant works better at preventing the cancer from returning.
Daphne, AlabamaAges 18 years+
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer?
- Yes. Clin2 currently lists 2,417 recruiting breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.